Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04518600 and Combinations in RR AML
NCT03390296Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivuxolimab in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2017; status: completed.
02
Drugs
ivuxolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03390296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390296.